Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247891 | 0.95 | PTPN1 (0.44) | PTPN1GRB2OPRM1OPRD1OPRK1 | |
| SCHEMBL31247949 | 0.93 | PTPN1 (0.44) | PTPN1GRB2OPRM1OPRD1OPRK1 | |
| SCHEMBL38652069 | 0.92 | PTPN1 (0.42) | PTPN1GRB2OPRM1OPRD1OPRK1 | |
| SCHEMBL30053792 | 0.91 | PTPN1 (0.47) | PTPN1GRB2 | |
| SCHEMBL30892072 | 0.91 | PSEN1 (0.42) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL30930720 | 0.87 | ACE (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30384997 | 0.87 | PTPN1 (0.47) | PTPN1 | |
| SCHEMBL31501260 | 0.87 | ABCB1 (0.41) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL31247975 | 0.86 | ABCB1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31247896 | 0.86 | PSEN1 (0.40) | OPRM1OPRD1OPRK1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400613-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400613-A1 | GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | PTPN1 554/4885GRB2 574/4885OPRM1 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.